Genmab A (GMAB) Net Cash Flow (2018 - 2026)

Genmab A (GMAB) has reported Net Cash Flow for 8 consecutive years, with -$22.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow rose 74.71% year-over-year to -$22.0 million; the trailing twelve-month figure through Jun 2026 stood at $82.0 million (down 83.41% YoY), and the FY2025 full-year result was $332.0 million, up 113.13% from the prior year.
• Net Cash Flow rose to -$22.0 million in Q2 2026 per GMAB's latest filing, from -$183.0 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $2.6 billion in Q1 2023 and bottomed at -$285.6 million in Q2 2024.
• Historically, Net Cash Flow has averaged $211.0 million across 5 years, with a median of -$10.1 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Net Cash Flow plunged 2296.29% in 2022, then soared 1511.51% in 2025.
• Over 5 years, Net Cash Flow stood at $12.2 million in 2022, then soared by 465.6% to $69.1 million in 2023, then jumped by 445.13% to $376.9 million in 2024, then fell by 0.77% to $374.0 million in 2025, then slumped by 105.88% to -$22.0 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$22.0 million, -$183.0 million, and $374.0 million for Q2 2026, Q1 2026, and Q3 2025 respectively.